相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
- Amgen
研究概览
简要总结
Expanded access requests for Olpasiran may be considered for adult participants with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD). To request access, use Responsible Party contact information provided in this record.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Approved For Marketing
不适用
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1Primary HyperoxaluriaNCT04125472Alnylam Pharmaceuticals
Approved For Marketing
不适用
Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)Familial Chylomicronemia SyndromeNCT06360237Ionis Pharmaceuticals, Inc.
Available
不适用
Expanded Access Program for OOS Obe-celLymphoblastic Leukemia, Acute, AdultB Cell ALLNCT06799221Autolus Limited
Approved For Marketing
不适用
Oral Berotralstat Expanded Access ProgramHAEProphylaxisHereditary AngioedemaNCT04428632BioCryst Pharmaceuticals
Approved For Marketing
不适用
An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA)Muscular Atrophy, SpinalNCT04256265Genentech, Inc.